NETSPOT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NETSPOT (NETSPOT).
Ga-68 dotatate is a somatostatin analog that binds to somatostatin receptors (SSTR2, SSTR5), enabling positron emission tomography (PET) imaging of SSTR-positive neuroendocrine tumors.
| Metabolism | Not metabolized; excreted unchanged via renal elimination. |
| Excretion | Primarily renal; approximately 50-60% of administered radioactivity excreted in urine within 24 hours, with fecal elimination accounting for <5%. |
| Half-life | Terminal elimination half-life of gallium-68 (complexed to DOTATATE) is approximately 1.1 hours for the radionuclide; the peptide conjugate has a half-life of about 2-3 hours, necessitating same-day imaging post-injection. |
| Protein binding | Approximately 30-40% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.2-0.4 L/kg, reflecting limited extravascular distribution consistent with a peptide targeting cell surface receptors. |
| Bioavailability | Not applicable; only administered intravenously, thus bioavailability is 100% by that route. |
| Onset of Action | Intravenous: Radiolocalization to somatostatin receptor-positive tissues occurs within minutes; optimal imaging at 40-60 minutes post-injection. |
| Duration of Action | Following intravenous administration, effective imaging window is approximately 2-4 hours due to rapid clearance; no therapeutic duration as it is a diagnostic agent. |
NETSPOT (gallium Ga 68 dotatate) is administered as a single intravenous dose of 148 MBq (4 mCi) for PET imaging.
| Dosage form | POWDER |
| Renal impairment | No specific dose adjustment is required for renal impairment; however, use with caution in severe renal impairment (GFR <30 mL/min) as elimination may be delayed. |
| Liver impairment | No specific dose adjustment is recommended for hepatic impairment based on Child-Pugh classification. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established; no standard dosing guidelines available. |
| Geriatric use | No specific geriatric dose adjustment is provided; use standard adult dose with consideration for age-related renal and hepatic decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NETSPOT (NETSPOT).
| Breastfeeding | It is not known whether gallium Ga 68 dotatate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from radiation exposure, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is not available. |
| Teratogenic Risk | NETSPOT (gallium Ga 68 dotatate) is a radiopharmaceutical. There are no adequate studies in pregnant women. Radioactive iodine, like other radiopharmaceuticals, can cause fetal harm. The risk is highest during the first trimester when organogenesis occurs. Use during pregnancy should be avoided unless the potential benefit justifies the potential risk to the fetus. No specific teratogenic effects are known. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to dotatate or any excipient."]
| Precautions | ["Risk of hypersensitivity reactions including anaphylaxis.","Radiation exposure; pregnancy category D.","Interpretation errors due to physiological uptake or inflammation.","Interference with long-acting somatostatin analogs (discontinue 3-4 weeks prior)."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of allergic reactions (e.g., rash, urticaria, dyspnea). No specific fetal monitoring is required; however, pregnancy status should be verified before administration. If inadvertent administration occurs, fetal radiation dose should be estimated and discussed with a radiation safety officer. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been conducted. Radiation exposure from gallium Ga 68 dotatate may theoretically affect gonadal function, but the short half-life and low activity used likely minimize risk. No specific fertility impact is reported. |